tbuckley/cabot-search huggingface dataset:
Somatic loss of the wild-type BRCA1 allele is not necessarily the first event in the pathogenesis of hereditary ovarian cancer: Implications for novel mechanism of acquired platinum resistance
Authors: E. Imyanitov, E. Savonevich, A. Ivantsov, G. Raskin, E. Kuligina, T. Gorodnova, E. Preobrazhenskaya, M. Kleshchov, V. Tiurin, A. Togo, A. Sokolenko
Journal: Annals of Oncology (2017)
Surveillance des syndromes grippaux en Angleterre et au Pays de Galles entre 1966 et 2006
Authors: A J Elliot, D M Fleming
Journal: Eurosurveillance (2006)

Les donnees de surveillance recueillies depuis 1966 a partir d’une base de donnees de medecins generalistes sont presentees ici. Les taux d’incidence des syndromes grippaux (SG) ont connu un pic pendant l’hiver de 1969/70, suivi d’une decennie d’activite accrue. Depuis lors, les SG tendent a diminuer progressivement, entrecoupes de periodes d’activite plus elevee en hiver ; depuis 1999/2000, l’incidence des syndromes grippaux est a son point le plus bas depuis 40 ans. Il semble que la decennie suivant les vagues annonciatrices de la pandemie pourrait avoir autant d’importance que la pandemie elle-meme pour la planification des services de soins dans la communaute.
Serum miRNA abundances discriminate imatinib-naive patients with advanced gastrointestinal stromal tumors (GIST) from those in remission on Imatinib therapy
Authors: H. Kosela Paterczyk, A. Paziewska, M. Kulecka, J. Karczmarski, M. Dabrowska, A. Kluska, A. Balabas, M. Piatkowska, M. Mikula, P. Rutkowski, J. Ostrowski
Journal: Annals of Oncology (2017)
Abstract 12052: Non-complement-Binding Donor Specific Antibodies and Cardiac-Allograft Vasculopathy in Pediatric Heart Transplant Recipients
Authors: Bibhuti Das, Chantale Lacelle, Song Zhang, David Fixler
Journal: Circulation (2016)

Aim: We hypothesized that the non-complement binding of de novo donor specific antibodies (DSA) detected after heart transplant (HT) confer a lower risk for acute rejections and coronary artery vasculopathy (CAV). The purpose of this study was to compare the clinical outcomes between pediatric HT recipients with C1q+ and C1q- fixing de novo DSA Methods: 127 patients from January 2005 to December 2014 were analyzed in this study to evaluate the outcomes including acute rejections and CAV of pediatric HT recipients who had C1q+ DSA compared to those with C1q- DSA. Serum samples from patients with circulating DSA were analyzed for C1q fixing according to the manufacturer’s protocol (C1qScreen, One Lambda). Results: Out of 127 patients transplanted between 2005 and 2014, 59 (46.4%) patients developed de novo DSA, of those 37 (62.7%) had C1q+ DSA. No difference in baseline characteristics: age at HT, gender, pre-HT diagnosis of CHD, ischemic time, number of HLA mismatch and pre-HT PRA &gt;10. We found that DSA strength is significantly associated with C1q+ (C-statistics 0.89 and p &lt;0.05) and at cut off 7000 MFI has 80% sensitivity and 80% specificity. C1q positive rate varied according to DSA class type: Class I (25% C1q+), class II (66% C1q +) and Class I and II (67% C1q+). C1q+ DSA patients had 2.4 times higher rate of acute rejection episodes compared to those with C1q- DSA. C1q+ DSA patients had significantly higher rates of CAV at 10-yr post-HT compared to C1q- DSA patients (72% vs 28%) (Figure) (P&lt;0.001). C1q+ DSA patients had a trend towards poor allograft survival at 10-yr post-HT compared to C1q-DSA patients (70% vs 52%) (p =0.15). Conclusions: De novo DSA which are C1q+ have significantly greater deleterious effect on long-term allograft outcome in pediatric heart transplant recipients. Thus, measuring DSA and determining their complement binding capacity is helpful in assessing the risk of cardiac allograft vasculopathy. Figure:
Crowdfunding for respiratory research: a new frontier for patient and public engagement?
Authors: Darrin P. Wiebe, J. Mark FitzGerald
Journal: European Respiratory Journal (2017)

The rapid expansion of social media has broadened the number of crowdfunding platforms available today. This phenomenon should be seen in the context of a long tradition of appealing to the public for financial support. Modern crowdfunding initiatives have developed into a significant source of funding, garnering an estimated US $5 billion annually, with proceeds projected to expand to an annual $100 billion by 2020 [1]. Websites such as Kickstarter.com allow users to pool the resources of many contributors, funding predefined initiatives [2] with incentives ranging from merchandise or symbolic gifts, to acknowledgement of project contribution [1]. Furthermore, there has been an interest in research-specific platforms to act as an adjunct to or replacement of traditional funding sources [3]. Entities such as Experiment.com offer a platform to seek crowdfunding support ranging from basic science initiatives [3] to clinical trials. A recent systematic search identified 20 clinical trials funded via crowdfunding, with eight out of 13 completed campaigns reaching their funding goals, the largest funding allocation reaching a total of $3 113 000 [4], underscoring the financial implications of crowdfunding. Crowdfunding is a novel mechanism of public involvement that has profound implications on respiratory research <http://ow.ly/2CsV30eEiVi>
Gene expression changes in the immunotherapy targets CTLA4 and LAG3 in right- and left-sided colorectal cancer tissues during preoperative oral uracil and tegafur/leucovorin chemotherapy
Authors: S. Sadahiro, T. Suzuki, A. Tanaka, K. Okada, G. Saito, H. miyakita, H. Nagase
Journal: Annals of Oncology (2017)
Cost effectiveness of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma patients in the UK
Authors: D. Palmer, P. Ross, T. Shah, D. Yu, S. Shergill, K. Patterson, N. Brereton, D. Lee
Journal: Annals of Oncology (2017)
Abstract 13273: Long-term Administration of Eicosapentaenoic Acid Prevents an Excessive Blood Pressure Elevation During Exercise Simulating Ordinary Activities of Daily Living via the Improvement of Vascular Endothelial Dysfunction in Patients With Hypertension
Authors: Akihiro Aoyama, Takashi Masuda, Misao Ogura, Ayako Akiyama, Yumi Kamada, Shinya Tanaka, Kentaro Kamiya, Nobuaki Hamazaki, Ryota Matsuzawa, Kohei Nozaki, Takeshi Nakamura, Kanae Yabu, Emi Maekawa, Junya Ako
Journal: Circulation (2015)

[Background] Excessive blood pressure (BP) elevation was frequently observed during exercise even at low or moderate intensity in patients with hypertension (HT), although their BP at rest was successfully controlled with antihypertensives. Several studies documented that vascular endothelial dysfunction induced excessive BP elevation in their ordinary activities of daily living (ADL). On the other hands, eicosapentaenoic acid (EPA) reduces oxidative stress and vascular inflammation resulting in the improvement of vascular endothelial dysfunction. However, it is still unknown whether long-term administration of EPA ameliorates excessive BP elevation in ordinary ADL. This study aimed to investigate the influence of EPA on vascular endothelial dysfunction and excessive BP elevation during exercise at moderate intensity in HT patients. [Methods] We recruited 60 HT outpatients whose resting blood pressure was successfully controlled below 140/90 mmHg. Patients were assigned to EPA(+) group or EPA(-) group in crossover method. They were administered antihypertensives with or without 1,800 mg of EPA daily for 10 months in the EPA(+) and EPA(-) groups, respectively. We measured serum concentrations of EPA, arachidonic acid (AA) and EPA/AA ratio. We assessed reactive hyperemia index (RHI) and thrombomodulin (TM) as a parameter of vascular endothelial function. BP elevation during exercise was determined as the difference from systolic BP (SBP) at rest to peak SBP during a cycle ergometer exercise test (SBP). The exercise intensity was given as 75% of peak heart rate (HR) obtained from a treadmill exercise test, which indicates the intensity of ordinary ADL. We compared all parameters between the two groups and analyzed the relationship between RHI and SBP. [Results] EPA, EPA/AA ratio and RHI were significantly higher in the EPA(+) group than in the EPA(-) group (P&lt;0.01, respectively). SBP and TM were significantly lower in the EPA(+) group than in the EPA(-) group (P&lt;0.05, respectively). RHI was negatively correlated with SBP (r=-0.313, P&lt;0.05). [Conclusion] Long-term administration of EPA prevented an excessive BP elevation during exercise simulating ordinary ADL via the improvement of vascular endothelial dysfunction in HT patients.
GW28-e1140 Evaluation of the Structure and Function of Left Atrium in Patients with Atrial Fibrillation after Left Atrial Appendage Occlusion by Transthoracic Echocardiography and Transesophageal Echocardiography
Authors: Weiwei Zhou, Sui Lun, Qi Miao, Du Jinpan, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
Subpleural cystic change in a patient with multiple rib exostoses
Authors: Maria Tsakok, Dinesh Addala, Clare Bradley, Alistair Moore, Fergus Gleeson
Journal: Thorax (2017)

A 75-year-old man, with hereditary multiple exostoses, had a positron emission tomography (PET)-CT scan for follow-up of an excised chondrosarcoma. Incidentally, he was found to have widespread subpleural cystic change (figure 1A and B) and a cystic right lower lobe lesion (figure 2) adjacent to a rib exostosis. He was referred to the urgent respiratory clinic on the basis of these unusual subpleural cystic findings and concern that the cystic right …
Primary pleomorphic sarcoma (PS) and leiomyosarcoma (LMS) of bone: Retrospective analysis of an original series
Authors: G.G. Baldi, A. Franchi, G. Soccianti, D.A. Campanacci, D. Greto, L. Livi, G. Roselli, F. Galardi, S. Bazzurri
Journal: Annals of Oncology (2017)
<i>Sleeping Beauty</i> Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors
Authors: Barbara R. Tschida, Nuri A. Temiz, Timothy P. Kuka, Lindsey A. Lee, Jesse D. Riordan, Carlos A. Tierrablanca, Robert Hullsiek, Sandra Wagner, Wendy A. Hudson, Michael A. Linden, Khalid Amin, Pauline J. Beckmann, Rachel A. Heuer, Aaron L. Sarver, Ju Dong Yang, Lewis R. Roberts, Joseph H. Nadeau, Adam J. Dupuy, Vincent W. Keng, David A. Largaespada
Journal: Cancer Research (2017)

Abstract Hepatic steatosis is a strong risk factor for the development of hepatocellular carcinoma (HCC), yet little is known about the molecular pathology associated with this factor. In this study, we performed a forward genetic screen using Sleeping Beauty (SB) transposon insertional mutagenesis in mice treated to induce hepatic steatosis and compared the results to human HCC data. In humans, we determined that steatosis increased the proportion of female HCC patients, a pattern also reflected in mice. Our genetic screen identified 203 candidate steatosis-associated HCC genes, many of which are altered in human HCC and are members of established HCC-driving signaling pathways. The protein kinase A/cyclic AMP signaling pathway was altered frequently in mouse and human steatosis-associated HCC. We found that activated PKA expression drove steatosis-specific liver tumorigenesis in a mouse model. Another candidate HCC driver, the N-acetyltransferase NAT10, which we found to be overexpressed in human steatosis–associated HCC and associated with decreased survival in human HCC, also drove liver tumorigenesis in a steatotic mouse model. This study identifies genes and pathways promoting HCC that may represent novel targets for prevention and treatment in the context of hepatic steatosis, an area of rapidly growing clinical significance. Cancer Res; 77(23); 6576–88. ©2017 AACR.
Safety and efficacy of gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis
Authors: J. Ventriglia, M.M. Laterza, B. Savastano, A. Petrillo, G. Tirino, L. Pompella, A. Pappalardo, M. Orditura, F. Ciardiello, F. De Vita
Journal: Annals of Oncology (2017)
GW28-e0959 Advanced oxidation protein products exacerbates cardiac remodeling via cardiomyocyte apoptosis in chronic kidney disease
Authors: Weijing Feng, Wanbing He, Yinyin Zhang, Mongheng Wang, Jingfeng Wang, Kun Zhang, Yu Liu, Jie Chen, Qingqing Cai, Hui Huang
Journal: Journal of the American College of Cardiology (2017)
Neuroblastoma PTPome analysis unveils association of DUSP5 and PTPN1 expression with poor prognosis
Authors: R. Pulido, O. Aurtenetxe, L. Zaldumbide, A. Erramuzpe, R. López, J.I. López, J.M. Cortés, C.E. Nunes-Xavier
Journal: Annals of Oncology (2017)
GW28-e0747 Update on New Test which Correctly Predicts Which Patients with Borderline Hypotension May Develop Hypotension in the Next 24 Hours
Authors: Thach Nguyen, Nhan Minh Tri Nguyen, Hanh Nguyen Hieu Le, Tuan Si Nguyen, Gianluca Rigatelli
Journal: Journal of the American College of Cardiology (2017)
The prevalence of CD146 expression in breast cancer subtypes and its relation to outcome
Authors: I.E. de Kruijff, A.M. Timmermans, M.A. den Bakker, A.M.A.C. Trapman, R. Foekens, E. Oomen-De Hoop, M. Smid, A. Fat - Hollestelle, C.H.M. van Deurzen, M.E. Meijer - van Gelder, J.A. Foekens, J.W.M. Martens, S. Sleijfer, A. Tjon
Journal: Annals of Oncology (2017)
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)
Authors: Charles S. Fuchs, Donna Niedzwiecki, Harvey J. Mamon, Joel E. Tepper, Xing Ye, Richard S. Swanson, Peter C. Enzinger, Daniel G. Haller, Tomislav Dragovich, Steven R. Alberts, Georg A. Bjarnason, Christopher G. Willett, Leonard L. Gunderson, Richard M. Goldberg, Alan P. Venook, David Ilson, Eileen O’Reilly, Kristen Ciombor, David J. Berg, Jeffrey Meyerhardt, Robert J. Mayer
Journal: Journal of Clinical Oncology (2017)

Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone. CALGB 80101 (Alliance; Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma) assessed whether a postoperative chemoradiotherapy regimen that replaced FU plus LV with a potentially more active systemic therapy could further improve overall survival. Patients and Methods Between April 2002 and May 2009, 546 patients who had undergone a curative resection of stage IB through IV (M0) gastric or gastroesophageal junction adenocarcinoma were randomly assigned to receive either postoperative FU plus LV before and after combined FU and radiotherapy (FU plus LV arm) or postoperative epirubicin, cisplatin, and infusional FU (ECF) before and after combined FU and radiotherapy (ECF arm). Results With a median follow-up duration of 6.5 years, 5-year overall survival rates were 44% in the FU plus LV arm and 44% in the ECF arm ( Plogrank = .69; multivariable hazard ratio, 0.98; 95% CI, 0.78 to 1.24 comparing ECF with FU plus LV). Five-year disease-free survival rates were 39% in the FU plus LV arm and 37% in the ECF arm ( Plogrank = .94; multivariable hazard ratio, 0.96; 95% CI, 0.77 to 1.20). In post hoc analyses, the effect of treatment seemed to be similar across all examined patient subgroups. Conclusion After a curative resection of gastric or gastroesophageal junction adenocarcinoma, postoperative chemoradiotherapy using a multiagent regimen of ECF before and after radiotherapy does not improve survival compared with standard FU and LV before and after radiotherapy.
Cabazitaxel followed by androgen deprivation therapy (ADT) significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A randomized, open label, phase III, multicenter trial
Authors: O. Andrén, A. Widmark, A. Falt, E. Ulvskog, S. Davidsson, C. Thellenberg Karlsson, M. Hjalm-Eriksson
Journal: Annals of Oncology (2017)
Comparison between magnetic resonance imaging (MRI) and pathology in the assessment of tumour regression grade (TRG) in rectal cancer (RC)
Authors: F. Sclafani, G. Brown, D. Cunningham, A. Wotherspoon, L. Sena Teixeira Mendes, J. Evans, C. Peckitt, R. Begum, D. Tait, J. Capdevila, B. Glimelius, S. Roselló, J. Thomas, J. Oates, I. Chau
Journal: Annals of Oncology (2017)
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group
Authors: Stuart M. Lichtman, R. Donald Harvey, Marie-Anne Damiette Smit, Atiqur Rahman, Michael A. Thompson, Nancy Roach, Caroline Schenkel, Suanna S. Bruinooge, Patricia Cortazar, Dana Walker, Louis Fehrenbacher
Journal: Journal of Clinical Oncology (2017)

Purpose Patients with organ dysfunction, prior or concurrent malignancies, and comorbidities are often excluded from clinical trials. Excluding patients on the basis of these factors results in clinical trial participants who are healthier and younger than the overall population of patients with cancer. Methods ASCO and Friends of Cancer Research established a multidisciplinary working group that included experts in trial design and conduct to examine how eligibility criteria could be more inclusive. The group analyzed current eligibility criteria; conducted original data analysis; considered safety concerns, potential benefits, research, and potential hurdles of this approach through discussion; and reached consensus on recommendations regarding updated eligibility criteria that prioritize inclusiveness without compromising patient safety. Results If renal toxicity and clearance are not of direct treatment-related concern, then patients with lower creatinine clearance values of > 30 mL/min should be included in trials. Inclusion of patients with mild to moderate hepatic dysfunction may be possible when the totality of the available nonclinical and clinical data indicates that inclusion is safe. Ejection fraction values should be used with investigator assessment of a patient's risk for heart failure to determine eligibility. Patients with laboratory parameters out of normal range as a result of hematologic disease should be included in trials. Measures of patient functional status should be included in trials to better assess fit versus frail patients. Conclusion Expanding inclusion of these patients will increase the number and diversity of patients in clinical trials and result in a more appropriate population of patients.
Cancer-associated malnutrition: Prevalence of cachexia, sarcopenia and impact on health-related quality of life and survival in a cohort of Irish ambulatory patients receiving chemotherapy.
Authors: Eadaoin Ni Bhuachalla, Louise Daly, Samantha Cushen, Deirdre O'Mahony, Richard Bambury, Seamus O'Reilly, Peter Mceneaney, Maria Twomey, Aoife M Ryan, Derek Gerard Power
Journal: Journal of Clinical Oncology (2016)

10137 Background: Malnutrition negatively impacts clinical outcomes in cancer pts. The prevalence of malnutrition in Irish oncology pts is unknown. Our aim was to assess the nutritional status of this cohort and the impact on quality of life (QOL) and survival. Methods: A cross sectional study of oncology out-pts presenting for chemotherapy between 2012–2016 at 2 university teaching hospitals was performed. A survey was devised, incorporating clinical, nutritional, biochemical and QOL data. Nutritional status was evaluated using cancer cachexia diagnostic criteria and CT assessment of muscle mass to define sarcopenia and myosteatosis. Cox proportional hazards model was used for survival analysis. Results: 726 pts with solid tumors were studied, 60% male with median age of 63 yrs (IQR 56-71yrs). Colorectal cancer was most prevalent (32%) and 45% had metastatic disease; 5% of the cohort was underweight, while the majority were either overweight or obese (56%). On CT analysis of body composition 51% had cancer cachexia, 42% sarcopenia, and 48% myosteatosis; 24% had both sarcopenia and myosteatosis. Regarding QOL, wt loss > 5% and cancer cachexia were associated with poorer global QOL score, and worse physical role, emotional and social function scores (all p < 0.005) and higher symptoms such as fatigue, nausea vomiting, pain, appetite loss and diarrhoea (all p < 0.05). Cancer cachexia, sarcopenia and myosteatosis were significantly associated with reduced survival, with the highest mortality risk in pts with both myosteatosis and sarcopenia. Median survival of these patients was 16.8 mths (95% CI 11.2-22.4 mths) vs 31.4 mths in those with normal body composition (95% CI 22.4 – 40.3 mths p= < 0.001). On multivariate analysis (controlling for age, sex, KPS, treatment intent and BMI) pts with both conditions had increased risk of mortality (HR 1.5, 95% CI 1.2-2.0, p= 0.003). Conclusions: Despite a normal or high BMI the rate of malnutrition and muscle wasting is high in oncology patients and has a significant negative impact on QOL and survival. The combination of sarcopenia and myosteatosis is an independent predictor of mortality.
An epidemiological insight into epithelioid sarcoma (ES): The open issue of distal-type (DES) versus proximal-type (PES)
Authors: A.M. Frezza, L. Botta, S. Pasquali, S. Stacchiotti, A. Gronchi, P.G. Casali, A. Trama, W.G. Rarecarenet
Journal: Annals of Oncology (2017)
La surveillance sentinelle utilisée pour étudier l’efficacité du vaccin anti-grippal : une étude pilote au Danemark
Authors: A Mazick, A H Christiansen, S Samuelsson, K Mølbak
Journal: Eurosurveillance (2006)

Le vaccin anti-grippal de la saison 2003/04 ne contenait pas la souche virale A(H3N2)/Fujian en circulation. Une evaluation de l’efficacite vaccinale (EV) etait necessaire, mais non disponible. Nous avons etudie si le systeme de surveillance base sur les laboratoires permettait une telle evaluation de l’EV. Une etude cas-temoin a ete menee au sein du systeme de surveillance sentinelle danois. Un cas a ete defini comme une personne de 25 ans ou plus avec une grippe A(H3N2)/Fujian/411/02. Quatre controles par cas, apparies sur les groupes d’âge et la date, ont ete selectionnes parmi les clients des medecins sentinelle (MS) qui avaient declare des cas. Ces medecins ont recueilli les donnees suivantes sur des questionnaires structures d’une page : statut vaccinal, maladies chroniques et vaccins anti-pneumococciques. Les questionnaires ont ete envoyes par la poste aux medecins participants pour estimer leur acceptabilite et la simplicite du recueil des donnees. 
Vingt-quatre cas ont ete identifies. Les donnees de 19 groupes cas-temoins ont ete analyses. Un controle a ete exclu par manque d’information sur le statut vaccinal. Deux des 19 cas et 11 des 75 temoins avaient ete vaccines contre la grippe. L’EV ajustee pour les maladies chroniques etait de 33% (95% IC 0%–88%) et de 37% (95% IC 0%–89%) si l’on excluait les cinq temoins presentant un syndrome grippal. Vingt-deux medecins ont retourne le questionnaire. Quinze medecins sur 17 n’ont pas eu de difficulte a trouver des temoins. Les medecins ont recueilli les donnees lors d’interviews avec les patients et a partir des notes cliniques, consacrant 1 a 5 minutes a chaque cas et 5 a 15 minutes pour les quatre temoins. Dix-neuf des 22 MS ont trouve que le temps passe sur l’enquete etait acceptable, 17 se disent prets a participer a une nouvelle etude, et aucun n’a ecarte l’idee d’une future collaboration.